Related Experiment Video
Updated: Jun 6, 2026
05:27
Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
Published on: July 20, 2022
Mitochondrial pharma-Q-genomics: targeting the OXPHOS cytochrome b
Aurora Gómez-Durán1, David Pacheu-Grau, Manuel J López-Pérez
1Departamento de Bioquímica, Biología Molecular y Celular, Centro de Investigaciones, Biomédicas En Red de Enfermedades Raras (CIBERER), Instituto Aragonés de Ciencias de la Salud (I+CS), Spain.
Drug Discovery Today
|November 30, 2010
Summary
Genetic variations in cytochrome b create unique coenzyme Q binding sites, impacting cellular energy production and disease risk. This discovery opens avenues for personalized medicine and novel drug development in mitochondrial pharmacogenomics.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Human cytochrome b genetic variations influence coenzyme Q binding pocket structure.
- These structural differences impact the efficiency of the oxidative phosphorylation system.
- Variations are linked to susceptibility to various medical conditions.
Purpose of the Study:
- To explore the implications of structural differences in cytochrome b.
- To investigate the potential for developing new drugs based on these variations.
- To establish the foundation for the field of mitochondrial pharmacogenomics.
Main Methods:
- Analysis of genetic variations in human cytochrome b.
- Structural modeling of coenzyme Q binding pockets.
- Assessment of oxidative phosphorylation coupling efficiency.
- Correlation with disease susceptibility.
Main Results:
- Identified structurally distinct coenzyme Q binding pockets due to genetic variation.
- Demonstrated altered coupling efficiency in the oxidative phosphorylation system.
- Established a link between these variations and susceptibility to medical conditions.
Conclusions:
- Cytochrome b genetic variations offer targets for therapeutic intervention.
- Structural differences can be leveraged for personalized medicine approaches.
- Mitochondrial pharmacogenomics represents a promising new field for drug development.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:43Electron Transport Chain: Complex III and IV
During the electron transport chain, electrons from NADH and FADH2 are first transferred to complexes I and II, respectively. These two complexes then transfer the electrons to ubiquinol, which carries them further to complex III. Complex III passes the electrons across the intermembrane space to Cyt c, which carries them further to complex IV. Complex IV donates electrons to oxygen and reduces it to water. As electrons pass through complexes I, III, and IV, the energy released aids the pumping...
01:30The Electron Transport Chain
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19Translocation of Proteins into the Mitochondria
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
01:39Mitochondrial Precursor Proteins
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial precursors...
Most of the mitochondrial precursors...